EYEPOINT INC

EyePoint CMO buys 4,875 shares amid a bullish surge, showing insider confidence in the drug‑device pipeline and future upside.

EyePoint CFO Elston George’s recent 7,500‑share purchase shows insider confidence, signaling a bullish outlook amid rising stock gains and potential drug approvals.

EyePoint CEO Jay Duker sells shares to a trust for $2.4 M, keeping his stake intact and boosting liquidity amid a volatile market and upcoming Duravyu data—what investors need to know.

EyePoint CFO’s sell‑buy trade shows portfolio reallocation, not a sell‑off, amid rising insider confidence and a 27% stock rebound.

EyePoint insider trading reveals a strategic shift: CMO Ribeiro Ramiro flips shares and options, hinting at short‑term gains amid upcoming clinical milestones.

EyePoint insider moves: CMO Ribeiro Ramiro’s disciplined buying and option selling signals confidence in future clinical milestones, hinting at upside potential for investors.

CEO insider buying at EyePoint signals long‑term confidence—discover what this move means for investors amid market volatility.